Mitomycin pyelocalyceal (Jelmyto)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 20:57, 6 November 2023 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. Formulated for pyelocalyceal infusion. =...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. Formulated for pyelocalyceal infusion.

Diseases for which it is used

History of changes in FDA indication

  • 2020-04-15: Approved for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). (Based on OLYMPUS)

Also known as

  • Brand name: Jelmyto
Retrieved from "https://hemonc.org/w/index.php?title=Mitomycin_pyelocalyceal_(Jelmyto)&oldid=80462"